SuperworthInfuSystem profit margin INFU
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 6.0%
- Operating margin, 12 months
- 9.3%
- Net margin on a year earlier
- +2.3 pts
- Peer median
- 7.8%
Over the twelve months to Jun 30, 2026, InfuSystem kept 6.0% of its revenue as net profit, with an operating margin of 9.3% and a gross margin of 57.5%.
Five years earlier its net margin was 15.2%.
The median for 10 medical instruments and supplies stocks of a similar size is 7.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 4.6% | 8.3% | 56.0% |
| FY2024 | 1.7% | 5.1% | 52.2% |
| FY2023 | 0.7% | 3.3% | 50.2% |
| FY2022 | 0.0% | 1.5% | 56.9% |
| FY2021 | 1.4% | 2.8% | 58.8% |
| FY2020 | 17.8% | 9.1% | 60.3% |
| FY2019 | 1.7% | 4.3% | 57.8% |
| FY2018 | −1.6% | 0.6% | 58.9% |
| FY2017 | −29.1% | −5.4% | 61.0% |
| FY2016 | −0.3% | 1.4% | 63.5% |
| FY2015 | 3.9% | 10.3% | 70.3% |
| FY2014 | 5.0% | 14.0% | 71.2% |
| FY2013 | 2.7% | 9.5% | 70.1% |
| FY2012 | −2.5% | 3.4% | 72.9% |
| FY2011 | −83.2% | n/a | 64.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 6.0% | +2.3 pts | 9.3% | |
| Q1 FY26 | 5.6% | +3.2 pts | 9.1% | |
| Q4 FY25 | 4.6% | +2.9 pts | 8.3% | |
| Q3 FY25 | 3.9% | +2.8 pts | 7.7% | |
| Q2 FY25 | 3.6% | +3.3 pts | 7.3% | |
| Q1 FY25 | 2.3% | +2.3 pts | 6.1% | |
| Q4 FY24 | 1.7% | +1.0 pts | 5.1% | |
| Q3 FY24 | 1.1% | +0.4 pts | 4.2% | |
| Q2 FY24 | 0.3% | −0.3 pts | 3.1% | |
| Q1 FY24 | 0.1% | +0.0 pts | 2.6% | |
| Q4 FY23 | 0.7% | +0.7 pts | 3.3% | |
| Q3 FY23 | 0.7% | +0.5 pts | 3.1% |
Against its peers
Companies in Medical - Instruments & Supplies nearest InfuSystem's size, closest first, today.
| Company | Profit margin |
|---|---|
| INFUInfuSystem | 6.0% |
| UTMDUtah Medical Products | 29.0% |
| EMBCEmbecta | 8.6% |
| PDEXPro DEX | 17.6% |
| TCMDTactile Systems Technology | 7.1% |
| MDXGMimedx | 1.8% |
| MOVMovado | 6.0% |
| KEQUKewaunee Scientific | 3.0% |
| IRMDIradimed | 26.7% |
| STAAStaar Surgical | 1.1% |
| BVSBioventus | 9.4% |
| Peer median | 7.8% |
Where InfuSystem ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on InfuSystem
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.